Tesaro Inc

Tesaro — Investor Presentation (January 2013)

29 slides from Tesaro's investor presentation, Jan 7, 2013

  1. Slide 1: January 2013 Corporate Presentation

    JANUARY 2013 CORPORATE PRESENTATION

  2. Slide 2: Company Summary

    COMPANY SUMMARY Novel cancer therapeutics Differentiated oncology supportive care agents Currently advancing three pipeline products Identify and in-license or acquire Fully develop and commercialize products in-house Commercial presence in core strategic markets Management team with highly relevant

  3. Slide 3: Product Portfolio Strategy

    Assemble and advance a balanced1 portfolio of cancer therapeutics and oncology supportive care agents, including: 1Balanced by stage, resource requirements and development risk PRODUCT PORTFOLIO STRATEGY 3 Compound Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Rolapitant Oral (NK-1 receptor antago

  4. Slide 4: Commercial Strategy

    Commercialize a portfolio of cancer therapeutics and supportive care products: 1. Deploy fully integrated sales, marketing and medical affairs organizations in core strategic markets: North America: United States, Canada Europe: Germany, France, UK, Italy, Spain Asia: China 2. Establish a comprehens

  5. Slide 5: Rolapitant Overview: Chemotherapy-Induced Nausea & Vomiting

    ROLAPITANT OVERVIEW CHEMOTHERAPY-INDUCED NAUSEA & VOMITING TESARO, INC.

  6. Slide 6: Rolapitant Overview

    ROLAPITANT OVERVIEW Acquired in December 2010 from OPKO Health Schering-Plough (S-P) divested to OPKO Health as an FTC condition for its merger with Merck Potentially a Best-in-Class cancer supportive care product candidate Potent and long-acting neurokinin-1(NK-1) receptor antagonist for chemothera

  7. Slide 7: CINV Is a Highly Debilitating Side-Effect of Chemotherapy

    CINV IS A HIGHLY DEBILITATING SIDE-EFFECT OF CHEMOTHERAPY Taste Change Patient Rankings of Chemotherapy Treatment Side Effects Source: Adapted from Sun et al., Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer, Support Care Can

  8. Slide 8: Mechanisms of CINV

    MECHANISMS OF CINV Chemotherapy NK1 receptors Substance P 5-HT3 receptors Serotonin Dorsal Vagal Complex Area postrema Brainstem GI tract Enterochromaffin Cell Serotonin Release Vagal Afferent 5-HT3 Receptors Peripheral Central 8

  9. Slide 9: Acute & Delayed CINV Driven by Different Neurotransmitters

    ACUTE & DELAYED CINV DRIVEN BY DIFFERENT NEUROTRANSMITTERS Intensity of Emesis Cisplatin (HEC) Cyclophosphamide/Carboplatin (MEC) Neurotransmitter 0 1 2 3 4 5 Days Adapted from Martin M. Oncology. 1996;53 (suppl 1):26-31. Patterns of Emesis: Highly vs. Moderately Emetogenic Chemotherapy SEROTONIN NE

  10. Slide 10: Phase 2 Design and Objectives

    PHASE 2 DESIGN AND OBJECTIVES Overview Trial Design Objectives Schering-Plough evaluated the safety and efficacy of rolapitant for the prevention of CINV in 454 patients receiving HEC for up to 6 cycles of chemotherapy Multicenter, randomized, double blind, placebo controlled clinical trial Compare

  11. Slide 11: Phase 2 Study Results

    PHASE 2 STUDY RESULTS Significantly greater CR rates compared to the control group Demonstrated safety and tolerability over multiple cycles of chemotherapy A rolapitant dose of 200 mg was selected for advancement into Phase 3 clinical trials Complete Response Rate (%) *Statistically significant Not

  12. Slide 12: Phase 2 Study Results: Nausea

    PHASE 2 STUDY RESULTS Demonstrated superior treatment effect for no significant nausea versus the control group in all CINV phases Validated questionnaire (FLIE1) demonstrated statistically significant better quality of life scores for the treatment group versus the control group *Statistically sign

  13. Slide 13: Rolapitant: A Potentially Differentiated NK-1 RA

    ROLAPITANT: A POTENTIALLY DIFFERENTIATED NK-1 RA1 Product / Product Candidate Status Single Dose Oral Single Dose IV No CYP 3A4 DDI Potential Potential to Prevent Nausea2 Rolapitant Phase 3 (oral) EMEND® (aprepitant Oral & fosaprepitant IV)3 Oral 3-Day; 2003 IV 150 mg; 2010 + - - Netupitant -palonos

  14. Slide 14: Rolapitant Highlights

    ROLAPITANT HIGHLIGHTS Highly potent, long acting NK-1 receptor antagonist Differentiation includes: Long half-life Reduced risk of CYP 3A4 drug interactions Rapid onset of activity Potential for reduction in significant nausea Phase 3 on-going and results anticipated 2H:13 Significant growth potenti

  15. Slide 15: Niraparib (PARP Inhibitor) Solid Tumors

    NIRAPARIB (PARP INHIBITOR) SOLID TUMORS TESARO, INC.

  16. Slide 16: Niraparib Overview

    NIRAPARIB OVERVIEW Poly (ADP-ribose) Polymerase (PARP) Inhibitor acquired in May 2012 from Merck Potential First and Best-in-Class Orally active and potent PARP 1/2 inhibitor Compelling pharmacologic properties Unlikely to have drug-drug interactions Viable formulation Global rights and strong Intel

  17. Slide 17: Niraparib Pre-Clinical Overview

    NIRAPARIB PRE-CLINICAL OVERVIEW Potent PARP inhibition on isolated target (IC50 4nM) and in cells (20-30nM) Active in BRCA xenograft models Prolonged PARP inhibition evident in tumors following treatment with niraparib (MK-4827) MDA-MB-436 (BRCA1-mut) Tumor Volume (mm3) Residual PARP Activity in MDA

  18. Slide 18: Phase 1 Design and Objectives

    PHASE 1 DESIGN AND OBJECTIVES Overview Trial Design Objectives First in human, open-label, Phase I study Completed enrollment Oral once daily dosing; two part study Dose escalation and expansion study (n=80) evaluating 30mg – 400mg of niraparib (MK-4827) Primary Objectives: Evaluate safety and toler

  19. Slide 19: Phase 1 Study Results

    PHASE 1 STUDY RESULTS Summary of activity overall in Phase 1 (n=80) PR 12/80 (15%); 10 ovarian, 2 breast SD 24/80 (30%); ovarian, breast, 3/3 lung, other SD > 12 weeks 18/80 (22.5%) Clinical activity in ovarian patients (n=39 evaluable) PR 10/39 (26%); SD 13/39 (33%) BRCA+ patients: PR 7/19 (37%); S

  20. Slide 20: Niraparib Development Plan

    NIRAPARIB DEVELOPMENT PLAN Design optimal development plan based upon: Phase 1 trial results Collective experience review of PARP inhibitor clinical studies Discussions with experienced clinical investigators and scientists Biomarker/patient selection strategy Potential cancer targets include breast

  21. Slide 21: TSR-011 (ALK Inhibitor) NSCLC and Other Cancers

    TSR-011 (ALK INHIBITOR) NSCLC AND OTHER CANCERS TESARO, INC.

  22. Slide 22: TSR-011 Overview

    TSR-011 OVERVIEW Global rights to AMGEN’s Anaplastic Lymphoma Kinase (ALK) Program acquired in March 2011 A potentially Best-in-Class molecularly targeted approach to treating certain cancer sub-populations TSR-011 is a highly selective and potent oral compound that possess desirable pharmaceutical

  23. Slide 23: ALK Inhibition Blocks Key Pathways for Cancer Cell Survival

    ALK INHIBITION BLOCKS KEY PATHWAYS FOR CANCER CELL SURVIVAL ALK-fusion first identified in lymphoma ALK activating mutations are present in NB and nearly 100% of NB overexpress ALK ALK-fusions (multiple partners) in NSCLC and CRC ALK amplification recently identified in inflammatory breast Cancer AL

  24. Slide 24: TSR-011 Pre-Clinical Overview

    TSR-011 PRE-CLINICAL OVERVIEW Excellent pharmaceutical properties Orally bioavailable, large volume of distribution, low clearance and long half-life predicted in humans Highly selective and significantly more potent than crizotinib; potentially: Less frequent dosing (more potent, longer acting) Sus

  25. Slide 25: TESARO ALK Inhibitors Show Excellent In Vivo Inhibition and Tumor Regression

    TESARO ALK INHIBITORS SHOW EXCELLENT IN VIVO INHIBITION OF ALK AND TUMOR REGRESSION Sustained ALK inhibition in vivo Slow off-rate may ensure prolonged ALK inhibition and tumor regression TESARO ALK inhibitors cause tumor regression in Karpas-299 tumors (ALCL) ALK inhibition in tumors is maintained

  26. Slide 26: TSR-011 Development Plan

    TSR-011 DEVELOPMENT PLAN Plan to develop TSR-011 patients with NSCLC whose tumors have altered ALK proteins Phase 1/2 study ongoing; study objectives: Determine the maximum tolerated dose of TSR-011 Define an optimal dosing schedule Assess safety and anti-tumor activity Data will provide an assessme

  27. Slide 27: Summary

    SUMMARY TESARO, INC.

  28. Slide 28: Summary

    SUMMARY Late stage oncology supportive care product Differentiated product profile Phase 3 data expected 2H:13 Significant market potential Rapidly advancing a development-stage pipeline of cancer therapeutics Potentially First and Best-in-Class PARP inhibitor Potentially Best-in-Class ALK inhibitor

  29. Slide 29: Mission Statement

    An oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and commercializing safer and more effective supportive care agents and therapeutics. MISSION STATEMENT 30

TESARO — Investor Presentation (January 2013) on 6ix